Tags

Type your tag names separated by a space and hit enter

Current Long-Term Pharmacotherapies for the Management of Obesity.
J Obes Metab Syndr. 2020 Jun 30; 29(2):99-109.JO

Abstract

Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m2. Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.

Authors+Show Affiliations

Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Sun Medical Center, Daejeon, Korea.Department of Family Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea.Department of Family Practice and Community Health, Ajou University Medical Center, Suwon, Korea.Department of Psychiatry, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.Department of Family Medicine, Korea University College of Medicine, Seoul, Korea.Department of Family Medicine, Eulji Hospital, Eulji University School of Medicine, Seoul, Korea.Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.Department of Family Medicine, Korea University College of Medicine, Seoul, Korea.Department of Surgery, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea.Department of Pediatrics, National Medical Center, Seoul, Korea.Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.Central St' Mary's Clinic Internal Medicine, Seoul, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.Department of Pediatrics, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea.Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32378399

Citation

Kim, Bo-Yeon, et al. "Current Long-Term Pharmacotherapies for the Management of Obesity." Journal of Obesity & Metabolic Syndrome, vol. 29, no. 2, 2020, pp. 99-109.
Kim BY, Kang SM, Kang JH, et al. Current Long-Term Pharmacotherapies for the Management of Obesity. J Obes Metab Syndr. 2020;29(2):99-109.
Kim, B. Y., Kang, S. M., Kang, J. H., Kim, K. K., Kim, B., Kim, S. J., Kim, Y. H., Kim, J. H., Kim, J. H., Nam, G. E., Park, J. Y., Son, J. W., Shin, H. J., Oh, T. J., Lee, H., Jeon, E. J., Chung, S., Hong, Y. H., & Kim, C. H. (2020). Current Long-Term Pharmacotherapies for the Management of Obesity. Journal of Obesity & Metabolic Syndrome, 29(2), 99-109. https://doi.org/10.7570/jomes20010
Kim BY, et al. Current Long-Term Pharmacotherapies for the Management of Obesity. J Obes Metab Syndr. 2020 Jun 30;29(2):99-109. PubMed PMID: 32378399.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current Long-Term Pharmacotherapies for the Management of Obesity. AU - Kim,Bo-Yeon, AU - Kang,Seon Mee, AU - Kang,Jee-Hyun, AU - Kim,Kyoung Kon, AU - Kim,Bomtaeck, AU - Kim,Seung Jun, AU - Kim,Yang-Hyun, AU - Kim,Jung-Hwan, AU - Kim,Jae Hyun, AU - Nam,Ga Eun, AU - Park,Ji Yeon, AU - Son,Jang Won, AU - Shin,Hye-Jung, AU - Oh,Tae Jung, AU - Lee,Hyug, AU - Jeon,Eon-Ju, AU - Chung,Sochung, AU - Hong,Yong Hee, AU - Kim,Chong Hwa, AU - ,, PY - 2020/01/15/received PY - 2020/02/27/revised PY - 2020/03/23/accepted PY - 2020/5/8/pubmed PY - 2020/5/8/medline PY - 2020/5/8/entrez KW - Liraglutide KW - Lorcaserin KW - Naltrexone/bupropion extended-release KW - Obesity KW - Orlistat KW - Phentermine/topiramate extended-release SP - 99 EP - 109 JF - Journal of obesity & metabolic syndrome JO - J Obes Metab Syndr VL - 29 IS - 2 N2 - Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m2. Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity. SN - 2508-7576 UR - https://www.unboundmedicine.com/medline/citation/32378399/Current_Long-Term_Pharmacotherapies_for_the_Management_of_Obesity DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.